News

Novo Nordisk debuts Wegovy in South Africa as weight-loss drugs race gathers pace

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
Marketplace10d

Makers of Wegovy, Zepbound face competition from compounding pharmacies

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Devdiscourse9d

Lilly's Weight Loss Pill Falls Short of Novo's Wegovy in Key Study

Eli Lilly's GLP-1 pill, orforglipron, led to 12.4% weight loss in a 72-week study, falling short of Novo Nordisk's Wegovy.

Lilly's obesity pill lags Novo's Wegovy injection in key trial

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

Eli Lilly Weight-Loss Pill Trial Disappoints, Offsetting Solid Profit and Sales

Results from a late-stage trial of Eli Lilly's experimental weight-loss pill were disappointing, sending shares of the ...

Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Lilly Signs $1.3 Billion Deal to Discover Obesity Medicines Using AI

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...